Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting
Presentation covers a research collaboration between Absorption Systems and Jade Therapeutics
EXTON, Pa., May 5, 2015 /PRNewswire/ -- The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs and safety testing of medical devices, announces that Dr. Glenwood Gum, Associate Director of Preclinical Studies, presented at this week's annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Denver, CO. The title of Dr. Gum's oral presentation was "Safety Assessment of a Novel, Cross-Linked, Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer in a Rabbit Ocular Surface Model."
The safety and tolerability of a proprietary, biodegradable polymer under development by Jade Therapeutics (based in Salt Lake City, UT) as a dry eye and corneal repair therapy was evaluated in a 28-day rabbit GLP study performed by Absorption Systems (with research facilities in Exton, PA; San Diego, CA; and Panama City, Panama). The material has been used commercially in veterinary applications and is now being developed for use in humans, both on its own and as a means of sustained ocular drug delivery. After 28 days with application of the test article six times per day, the test article was extremely well tolerated, with no clinical anomalies, no changes in corneal thickness of intraocular pressure, and no signs of inflammation or toxicity.
Absorption Systems is a preclinical contract research organization with particular expertise in assessing the safety and efficacy of drugs and medical devices, and the distribution of drugs, in the eyes of healthy animals and in ocular disease models. Jade Therapeutics focuses on the use of locally administered polymer technologies – either on a standalone basis or to deliver drugs and biologics in a sustained-release manner – for the treatment and/or prevention of ophthalmic diseases, conditions, and injuries.
The ARVO meeting features thousands of the world's leading researchers on ophthalmology, including ocular diseases and ophthalmic drugs, devices, and drug delivery. The program, which is truly international in scope, covers five full days (May 3-7).
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for in vitro drug interaction assessment. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Panama, serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit www.absorption.com.
About Jade Therapeutics, Inc.
Jade Therapeutics develops locally administered, polymer-based products designed to treat poorly served ophthalmic indications. The Company's proprietary, cross-linked, bio-erodible hydrogel technology has demonstrated a variety of unique and beneficial characteristics, whether employed alone or as a sustained-release drug-delivery vehicle. This approach could enable improved therapeutic outcomes along with increased patient compliance to therapy, decreased frequency of administration and office visits, and avoidance of subsequent surgeries – ultimately resulting in better visual outcomes with enhanced quality of life. Importantly, Jade's products benefit from relatively short clinical/regulatory pathways, and the Company's use of approved and/or well-tested bioactive agents significantly decreases development risk. Additional information about Jade can be obtained at www.jadetherapeutics.com.
Chris Bode
Absorption Systems
1-610-280-1451
[email protected]
www.absorption.com
SOURCE Absorption Systems
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article